Analyst Price Target is $29.00
▲ +3.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Fortrea in the last 3 months. The average price target is $29.00, with a high forecast of $31.00 and a low forecast of $27.00. The average price target represents a 3.83% upside from the last price of $27.93.
Current Consensus is
The current consensus among 2 contributing investment analysts is to reduce stock in Fortrea. This Reduce consensus rating has held steady for over two years.
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina.